ArticleFrontiers in oncology2018
Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis.
Article in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 1 synthesis or guideline pooled it, 178 citations in OpenAlex.
- Detection rate of gastrin-releasing peptide receptor (GRPr) targeted tracers for positron emission tomography (PET) imaging in primary prostate cancer: a systematic review and meta-analysis.Annals of nuclear medicine · 2024Pooled it
- Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study.European journal of nuclear medicine and molecular imaging · 2026Trial
- Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [European urology · 2024Trial
- QuantitativeRadiology · 2024Trial
- Safety Analyses of the Phase 3 VISION Trial of [European urology · 2024Trial
- Incremental Impact of [Molecular imaging and biology · 2022Trial
- Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.The New England journal of medicine · 2021Trial
- Baseline Ga-68 PSMA PET/CT-derived volumetric parameters as predictors of biochemical recurrence following radical prostatectomy.Annals of nuclear medicine · 2026Article
- An interpretable biparametric MRI habitat radiomics model for predicting bone metastasis in prostate cancer: a dual-center study.Translational andrology and urology · 2026Article
- Estimation of Future Patient Populations Eligible for Radioligand Therapies in the EU and the UK: A Modelling Study.The Lancet regional health. Europe · 2026Article
- Estimation and Correction of the Partial Volume Effect Using Personalized Phantoms of Lymph Node Metastases in Lutetium 177 SPECT/CT Dosimetry.Molecular imaging and biology · 2026Article
- Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer.Nature reviews. Urology · 2026Review
- Istanbul PSMA PET/CT criteria (IPPC): an imaging-based approach to patient selection for active surveillance.European journal of nuclear medicine and molecular imaging · 2026Article
- A phase II study evaluating pharmacokinetics and dosimetry ofEJNMMI research · 2026Article
- Prostate specific membrane antigen (PSMA) as a biomarker in early and localized advanced prostate cancer: a narrative review.The Canadian journal of urology · 2026Review
- Focusing on Prostate-Specific Membrane Antigen in Precision Diagnosis and Treatment of Prostate Cancer.Biomedicines · 2026Review
- Inhibition of Growth and Induction of Apoptosis of Human Prostate Cancer Cells by Enzymatic Blockage of Kallikreins.Prostate cancer · 2026Article
- Review
- Preclinical Evaluation of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- The expression of prostate-specific membrane antigen in intraductal carcinoma of the prostate.Scientific reports · 2025Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.